EUVIMEDEUVIMED entdecken
Multizentrische Studie

Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study

Zhenglin Yi, Huihuang Li, Mingyong Li, Jiao Hu, Zhiyong Cai, Zhi Liu, Chunyu Zhang, Chunliang Cheng, Yunbo He, Jinbo Chen, Xiongbing Zu, Ruizhe Wang

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-05286-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Urology, 2024. Verfasst von Zhenglin Yi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Huxiang Youth Talent Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Determining the potential benefit of neoadjuvant androgen deprivation therapy (ADT) and adjuvant ADT in patients with locally advanced prostate cancer (LAPC) undergoing complete resection. METHODS: 139 patients diagnosed with cT3-4, or cN+ LAPC in Xiangya Hospital and The First Affiliated Hospital of University of South China from 2010 to 2021 were collected. Cancer-specific survival (CSS) and overall survival (OS) of patients were assessed using Kaplan-Meier and Cox proportional risk analysis. We also analyzed the functional outcomes of two subgroups of patients who underwent radical prostatectomy (RP). RESULTS: Of the 182 patients with cT3-4, or cN+ LAPC, 139 patients (76.4%) were enrolled in the study with a 5-year survival rate of 82.3%. 45 patients (32.4%) received ADT alone, 46 patients (33.1%) received neoadjuvant ADT before surgery, and the remaining 48 patients (34.5%) received surgery with adjuvant ADT. Neoadjuvant ADT before surgery and surgery with adjuvant ADT were associated with significantly improved survival compared with ADT alone. Multivariate Cox models showed that neoadjuvant ADT before surgery (hazard ratio [HR], 0.29; 95% CI 0.13-0.92) or surgery with adjuvant ADT (HR, 0.26; 95% CI 0.16-0.78) was associated with improved CSS compared with ADT alone. Regional lymph node metastasis, positive lymphovascular invasion, and Gleason score 9 + were independent predictors of LAPC CSS and OS. More patients in the neoadjuvant ADT before surgery group achieved final continence status within 12 months after surgery (93.48% v 77.08%). CONCLUSION: CSS and OS were significantly prolonged in cT3-4, or cN+ LAPC patients who received neoadjuvant ADT before surgery and surgery with adjuvant ADT compared to ADT alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsNeoadjuvant TherapyHumansMaleRetrospective StudiesAgedMiddle AgedChemotherapy, AdjuvantNeoplasm StagingProstatectomySurvival Rate

Stichwörter der Autor:innen

Androgen deprivation therapyCancer-specific survivalLocally advanced prostate cancerOverall survivalRadical prostatectomy

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • The First Affiliated Hospital, Urology department, Hengyang Medical School, University of South China, Hengyang, China.
  • Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. zuxbxyyy@126.com.
  • Department of Urology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China. zuxbxyyy@126.com.
  • Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China. ruizhe07@qq.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Huxiang Youth Talent Support Program
  • Fundamental Research Funds for Central Universities of the Central South University

Zitieren

APA

Yi, Z., Li, H., Li, M., Hu, J., Cai, Z., Liu, Z., Zhang, C., Cheng, C., He, Y., Chen, J., Zu, X., & Wang, R. (2024). Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study. World Journal of Urology. https://doi.org/10.1007/s00345-024-05286-6

Vancouver

Yi Z, Li H, Li M, Hu J, Cai Z, Liu Z, et al. Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study. World Journal of Urology. 2024. doi:10.1007/s00345-024-05286-6

BibTeX
@article{Yi2024,
  author = {Yi, Zhenglin and Li, Huihuang and Li, Mingyong and Hu, Jiao and Cai, Zhiyong and Liu, Zhi and Zhang, Chunyu and Cheng, Chunliang and He, Yunbo and Chen, Jinbo and Zu, Xiongbing and Wang, Ruizhe},
  title = {Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-05286-6}
}
Kostenlos starten →